4O5I image
Deposition Date 2013-12-19
Release Date 2014-04-16
Last Version Date 2024-11-20
Entry Detail
PDB ID:
4O5I
Title:
Crystal structure of broadly neutralizing antibody F045-092 in complex with A/Victoria/361/2011 (H3N2) influenza hemagglutinin
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
6.50 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Hemagglutinin HA1 chain
Gene (Uniprot):HA
Chain IDs:A, C, E, G, I, K
Chain Length:323
Number of Molecules:6
Biological Source:Influenza A virus
Polymer Type:polypeptide(L)
Molecule:Hemagglutinin HA2 chain
Gene (Uniprot):HA
Chain IDs:B, D, F, H, J, L
Chain Length:176
Number of Molecules:6
Biological Source:Influenza A virus
Polymer Type:polypeptide(L)
Molecule:Fab F045-092 heavy chain
Chain IDs:M, O, Q, S, U, W
Chain Length:240
Number of Molecules:6
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Fab F045-092 light chain
Chain IDs:N, P, R, T, V, X
Chain Length:216
Number of Molecules:6
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
ASN L ASN GLYCOSYLATION SITE
Ligand Molecules
Primary Citation
Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus.
Nat Commun 5 3614 3614 (2014)
PMID: 24717798 DOI: 10.1038/ncomms4614

Abstact

Influenza viruses present a significant health challenge each year, as in the H3N2 epidemic of 2012-2013. Here we describe an antibody, F045-092, that possesses broadly neutralizing activity against the entire H3 subtype and accommodates the natural variation and additional glycosylation in all strains tested from 1963 to 2011. Crystal structures of F045-092 in complex with HAs from 1975 and 2011 H3N2 viruses reveal the structural basis for its neutralization breadth through insertion of its 23-residue HCDR3 into the receptor-binding site that involves striking receptor mimicry. F045-092 extends its recognition to divergent subtypes, including H1, H2 and H13, using the enhanced avidity of its IgG to overcome lower-affinity Fab binding, as observed with other antibodies that target the receptor-binding site. This unprecedented level of antibody cross-reactivity against the H3 subtype can potentially inform on development of a pan-H3 vaccine or small-molecule therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures